Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$169.83M

FY 2025 · Annual

Net Income

-$161.31M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.66M7.03M000
Cost of Revenue001.71M2.13M0
Gross Profit5.66M7.03M(1.71M)(2.13M)0
Gross Margin100.0%100.0%———
Research & Development25.85M28.4M48.22M112.47M133.72M
Selling, General & Admin6.15M8.01M12.48M30.13M36.11M
Operating Expenses32M36.41M60.7M140.47M169.83M
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
EBITDA(25.76M)(27.78M)(58.47M)(125.2M)(159.02M)
EBITDA Margin-455.5%-395.4%———
Operating Income(26.35M)(29.38M)(62.41M)(142.6M)(169.83M)
Operating Margin-465.8%-418.3%———
Interest Income1K565K2.28M15.36M9.09M
Interest Expense3K65K187K142K489K
Other Income / Expenses(4K)491K2.04M15.13M8.52M
Income Before Tax(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Pre-Tax Margin-465.9%-411.3%———
Income Tax Expense00000
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Net Margin-465.9%-411.3%———
EPS (Basic)(1.02)(1.12)(0.00)(3.33)(3.64)
EPS (Diluted)(1.02)(1.12)(0.00)(3.33)(3.64)
Weighted Avg Shares25.8M25.8M673.62M38.33M44.26M
Weighted Avg Shares (Diluted)25.8M25.8M673.62M38.33M44.26M

KYTX Earnings Waterfall · TTM

NASDAQ:KYTX · Revenue to Net Income

Key Ratios

EPS$-3.28
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.2
P/S Ratio0.0

Analysis

$0 of revenue converted into -$156.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.28, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingOct 19, 2026
8-KCurrent reportSep 24, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

How much revenue does KYTX generate?

Kyverna Therapeutics, Inc. (KYTX) reported $0.00 of revenue in fiscal 2025.

Is KYTX profitable?

Kyverna Therapeutics, Inc. (KYTX) reported -$161.31M of net income.